Interleukin-1 beta (IL-1B) (IL-1B)

Interleukin-1 beta (IL-1β) is a pivotal pro-inflammatory cytokine belonging to the interleukin-1 family, primarily produced by activated macrophages, monocytes, and dendritic cells (UniProt: P01584). It is synthesized as an inactive precursor, pro-IL-1β, which requires proteolytic cleavage by the enzyme caspase-1 within the inflammasome complex to become biologically active (PubMed: 28192390). Once active, IL-1β mediates a wide range of immune and inflammatory responses, including the induction of fever, the activation of T-cells, and the stimulation of other inflammatory mediators like IL-6 (StatPearls: NBK544240). Pathologically, overproduction or dysregulation of IL-1β is a key driver in autoinflammatory diseases such as Cryopyrin-Associated Periodic Syndromes (CAPS), as well as chronic conditions like rheumatoid arthritis, gout, and atherosclerosis (PubMed: 30107174). Therapeutic targeting of IL-1β signaling is achieved through various modalities, including monoclonal antibodies like canakinumab that neutralize the cytokine, or receptor antagonists like anakinra that block its binding to the IL-1 receptor (NIH: PMC7122264). These interventions are highly effective in reducing systemic inflammation but carry risks such as an increased susceptibility to opportunistic infections (PubMed: 29144955).

Other names

IL-1 betaCatabolinIL1F2Interleukin-1 betaIL1B

Interleukin-1 beta signaling is inhibited through several mechanisms: direct neutralization of the circulating cytokine by monoclonal antibodies (e.g., canakinumab), competitive inhibition of the Interleukin-1 receptor (IL-1R1) by recombinant receptor antagonists (e.g., anakinra), or by using trap molecules that consist of cytokine-binding domains of the receptor fused to an Fc portion (e.g., rilonacept) (NIH: PMC7122264).